AstraZeneca gains a speedy Imfinzi review in race to beat Roche on frontline SCLC
Well, Roche’s Tecentriq had a good few-month run as the lone frontline immunotherapy on the small-cell lung cancer market. That reign may soon end. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
